Shen Yang Tonglian Group Co., Ltd.

Shenyang Fuyang Pharmaceutical Technology Co., Ltd.

China Petroleum Chemical Corporation

Dalian Research Institute of Petroleum and Petrochemicals, Sinopec Corp.

Shen Yang Fuyang Medicine Technology Co., Ltd.

Yang Jiang

Xiaofeng Zhao

Yiguang Wang

Weiqing He

Yuyou Hao

Minghua Guan

Xiuna Yang

Zonglin Ruan

Enhong Jiang

Jiawen Zhou

Jianlu Dai

Shengwu Yang

Haochen Wang

Guoying Cui

Weinqing He

Xulein Jiang

An upflow reactor (), includes a housing (), a catalyst bed layer () and a pressing device (). The housing () is internally provided with a reaction chamber (), a reaction material inlet () and a reaction material outlet () which are in communication with the reaction chamber () are provided on the housing (). The catalyst bed layer () is provided within the reaction chamber (), the pressing device () is provided within the reaction chamber () and located above the catalyst bed layer (). At least a part of the pressing device () is movable up and down so that the at least a part of the pressing device () can be pressed against the catalyst bed layer ().

Upflow reactor

Use of carrimycin ininfection resistance comprises the main steps: measuring the activity of carrimycin inresistance by adopting an absolute concentration method through taking clinical first-line antituberculotics, i.e., isoniazid and rifampicin as controls. The result indicates that carrimycin has obvious superior activity to clinically-separatedincluding drug-resistant bacteria compared with those of the clinical first-line control drugs, i.e., the isoniazid and the rifampicin, and use of carrimycin in manufacturing drugs for treating tubercleinfected diseases are expected to be developed.

Use of carrimycin ininfection resistance

The present disclosure provides a biosynthetic gene cluster of carrimycin. The biosynthetic gene cluster comprises 44 gene open reading frames (orf), i.e., 5 orfs (orf10-14) encoding polyketide synthase, 9 orfs (orf1, 4-6, 15 and 36-39) related to polyketone synthesis extension unit and modification, 16 orfs (orf9, 16-22, 24, 26, 28, 29, 33-35 and 41) related to glycosyl synthesis, 6 orfs (orf7, 8, 30-32 and 40) related to glycosyl transfer, 2 orfs (orf3 and 25) related to resistance, 4 orfs (orf2, 23, 27 and 42) possibly related to regulation, a tsr resistance marker gene orf (orf43) and a 4&#x2033;-mycaroseglucoside isovaleryl transferase gene orf (orf44).

Biosynthetic gene cluster of carrimycin

The present invention relates to levocarrimycin, its pharmaceutical compositions, preparation methods and application. Levocarrimycin is a mixture of isovalerylspiramycin III, II and I as main components and contains some isobutyrylspiramycin III and II, butyrylspiramycin III and II, propionylspiramycin III and II, as well as acetylspiramycin III and II, among which, the content of isovalerylspiramycin III is no less than 30 wt %, the total content of isovalerylspiramycin III, II and I is no less than 60 wt %, and the content of acylspiramycin is 80-98 wt %. Specific optical rotation of said levocarrimycin is [&#x3b1;]=&#x2212;52&#xb0;&#x2dc;&#x2212;57&#xb0; in the solution of 0.02 g/ml chloroform at temperature of 25&#xb0; C. The present invention also relates to the crystalline compound of isovalerylspiramycin III, II or I in levocarrimycin, and pharmaceutical compositions containing the said levocarrimycin. In present invention, the active components in levocarrimycin or its pharmaceutical compositions have optical activity and excellent anti-infective effect.

Levocarrimycin, pharmaceutical compositions, preparation methods and uses thereof

Disclosed are levoisovalerylspiramycin I, II or III, preparations, preparing methods and uses thereof. The preparations comprise levoisovalerylspiramycin I, II or III and pharmaceutically acceptable carrier and/or adjuvant, wherein the purity of levoisovalerylspiramycin I, II or III is above 90 wt %. The levoisovalerylspiramycin I, II or III has a good antibacterial activity, and the preparations include solution for injection, powder for injection or lyophilized powder for injection.

Levoisovalerylspiramycin I, II or III, preparations, preparation methods and uses thereof

A genetically engineered strain WSJ-IA for producing isovaleryl spiramycin I. Also provided is a method for preparing the strain, including the steps of: (a) constructing a recombinant plasmid including a double gene ist-acyB2; (b) transforming the plasmid into an isovaleryl spiramycin I-producing strain to obtain the strain WSJ-IA. The level of isovaleryl spiramycin I produced by fermentation of the strain WSJ-IA is increased 1.7 times and the fermentation potency thereof increased 4.14 times in comparison with the strain exclusively including a single gene ist.

Genetically engineered strain WSJ-IA for producing isovaleryl spiramycin I

Growing community of inventors

Liaoning, China

Yang Jiang